Answers are grounded in this paper and cite their sources.
Eravacycline is a novel tetracycline antibiotic approved for complicated intraabdominal infections. Recent reports have suggested a potential association with hypofibrinogenemia, but real-world data are limited. The purpose of this study was to investigate the temporal profile and associated coagulation abnormalities of hypofibrinogenemia in patients receiving eravacycline in a real-world cohort. A retrospective observational study was conducted on patients who received eravacycline treatment at a tertiary care center from December 2023 to December 2025. Clinical data of the enrolled patients were collected, and the incidence of hypofibrinogenemia occurring during eravacycline therapy was calculated. The clinical characteristics of patients with hypofibrinogenemia were summarized. Among the 31 patients who received eravacycline for at least 72 h, 7 patients (22.6%) experienced a decline in blood fibrinogen levels (fibrinogen < 2.0 g/L). The median time to the first detected decrease in fibrinogen levels was 4 days, and the median time to nadir was 8 days among affected patients. Fibrinogen decline during eravacycline therapy is frequently accompanied by d -dimer elevation and thrombocytopenia. There was a temporal association between eravacycline exposure and fibrinogen decline, which was typically observed within the first week of therapy and was frequently accompanied by d -dimer elevation.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: